These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49. New expanded access drugs for use in combination therapy. Notes Undergr; 1998; (No 37):suppl 1-2. PubMed ID: 11365823 [TBL] [Abstract][Full Text] [Related]
50. FDA approves Sustiva (efavirenz) capsules, first once-daily anti-HIV drug. Food and Drug Administration. Res Initiat Treat Action; 1998 Oct; 4(6):13-4. PubMed ID: 11365915 [TBL] [Abstract][Full Text] [Related]
52. Raising levels of amprenavi. AIDS Patient Care STDS; 2000 Nov; 14(11):618. PubMed ID: 11155905 [No Abstract] [Full Text] [Related]
53. Efavirenz + emtricitabine + tenofovir: new combination. HIV infection: do not modify ongoing therapy just to use one less tablet. Better adherence than with separate dosing has not been demonstrated, while reduced efficacy is plausible. Prescrire Int; 2009 Jun; 18(101):105. PubMed ID: 19637416 [No Abstract] [Full Text] [Related]
54. DMP 266 study opens at Jefferson. Crit Path AIDS Proj; 1997; (No 32):30-1. PubMed ID: 11364440 [TBL] [Abstract][Full Text] [Related]
55. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen. Scherpbier HJ; Bekker V; Pajkrt D; Jurriaans S; Lange JM; Kuijpers TW Pediatrics; 2007 Mar; 119(3):e705-15. PubMed ID: 17308244 [TBL] [Abstract][Full Text] [Related]